Unveiling the Burden of Drug-Induced Impulsivity:

1

2 A Network Analysis of the FDA Adverse Event Reporting System. 3 Running Title: The burden of drug-induced Impulsivity 4 Authors: Michele Fusaroli#<sup>a[\*]</sup>, Stefano Polizzi#<sup>b</sup>, Luca Menestrina#<sup>c</sup>, Valentina Giunchi<sup>a</sup>, Luca 5 Pellegrini<sup>d,e</sup>, Emanuel Raschi<sup>a</sup>, Daniel Weintraub<sup>f,g</sup>, Maurizio Recanatini<sup>c</sup>, Gastone Castellani<sup>b</sup>, 6 7 Fabrizio De Ponti<sup>a</sup>, Elisabetta Poluzzi<sup>a</sup>. 8 #Equally contributed 9 **Affiliations**: 10 <sup>a</sup>Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. 11  $^b$ Unit of Medical Physics, Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, 12 13 <sup>c</sup>Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, 14 40126 Bologna, Italy 15  $^a$ Hertfordshire Partnership NHS University Foundation Trust, Highly Specialised OCD and BDD Service, Rosanne 16 House, Parkway, Welwyn Garden City, Hertfordshire, UK 17 <sup>e</sup>School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire, UK 18  $^f$ Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19 <sup>9</sup>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical 20 Center, Philadelphia, PA 21 22 Figures: 7 Tables: 3 23 **Word count**: 4,657 24 25 26 [\*]michele.fusaroli2@unibo.it 27

# **Abstract**

28

- 29 Introduction: Impulsivity induced by dopaminergic agents, like pramipexole and
- aripiprazole, can lead to behavioral addictions impacting social functioning and quality of life
- 31 of patients and families (e.g., resulting in unemployment, marital problems, anxiety). These
- 32 secondary effects, interconnected in networks of signs and symptoms, are usually overlooked
- 33 by clinical trials, not reported in package inserts, and neglected in clinical practice.
- 34 **Objective:** This study explores the syndromic burden of impulsivity induced by pramipexole
- and aripiprazole, pinpointing key symptoms for targeted mitigation.
- 36 Methods: An event-event Information Component (IC) on the FDA Adverse Event Reporting
- 37 System (January 2004 March 2022) identified the syndrome of events disproportionally co-
- 38 reported with impulsivity, separately for pramipexole and aripiprazole. A greedy-modularity
- 39 clustering on composite network analyses (PPMI, Ising,  $\Phi$ ) identified subsyndromes.
- 40 Bayesian network modeling highlighted possible precipitating events.
- 41 **Results:** Suspected drug-induced impulsivity was documented in 7.49% pramipexole and
- 42 4.50% aripiprazole recipients. The highest IC concerned obsessive-compulsive disorder
- 43 (reporting rate = 26.77%; IC median = 3.47, 95%CI = 3.33-3.57) and emotional distress
- 44 (21.35%; 3.42, 3.26-3.54) for pramipexole, bankruptcy (10.58%; 4.43, 4.26-4.55) and divorce
- 45 (7.59%; 4.38, 4.19-4.53) for aripiprazole. The network analysis identified delusional jealousy
- and dopamine dysregulation subsyndromes for pramipexole, obesity-hypoventilation and
- 47 social issues for aripiprazole. The Bayesian network highlighted anxiety and economic
- 48 problems as potentially precipitating events.
- 49 **Conclusion**: The under-explored consequences of drug-induced impulsivity significantly
- 50 burden patients and families. Network analyses, exploring syndromic reactions and potential
- 51 precipitating events, complement traditional techniques and clinical judgment. Characterizing
- 52 the secondary impact of reactions will support informed patient-centered decision-making.
- **Keywords**: adverse drug reactions; quality of life; pramipexole; aripiprazole; impulse control
- 55 disorders

53

- 57 Highlights
- 58• Drug-induced impulsivity significantly impacts patients' lives. Network analyses help
- 59 characterize reactions as syndromes.
- 60• We explore the impulsivity syndrome and subsyndromes resulting from pramipexole and
- 61 aripiprazole.
- 62• The manifestation of drug-induced impulsivity was different for the two drugs. Anxiety and
- 63 economic problems bridge between other symptoms and could be important therapeutical
- 64 targets.

#### 1. Introduction

Adverse drug reactions (ADRs) significantly impact patients' well-being [1], extending from organic to psychological and social issues [2,3]. For instance, immunodeficiency perturbs social activities, dysphonia hinders the ability to function in positions requiring extensive vocal communication such as teaching or other public-facing roles, and sexual dysfunction can affect relationships and even personal identity, with further cascading effects on psychological and physical well-being. Despite their profound effects and complex networks of interactions, ADRs are often inadequately recognized, resulting in compromised patient-doctor relationships [4], prolonged hospitalization [5], and a pervasive decline in quality of life (QoL) [6]. Evidence obtained from patient-reported outcomes – crucial for QoL assessment and patient-centered care [7] – is equally disregarded and often relegated to the margins in prescribing information or package inserts [8].

Drug-induced impulsivity, classified as "impulse control disorders induced by other specified psychoactive substance (6C4E.73)" in the International Classification of Diseases (ICD-11) category of disorders due to substance use, represents a distressing group of conditions marked by a loss of behavioral control. This pathological disinhibition can yield behaviors as pervasive as pathologic gambling, hypersexuality, compulsive shopping, and hyperphagia—the so-called "four knights of Impulse Control Disorder", all with important further repercussions on social relationships, physical and psychological wellbeing [9]. Other behaviors like stealing, hair pulling, and compulsive hoarding, while less acknowledged, can also occur, and further diversify potential manifestations of drug-induced impulsivity [10,11].

The first reports of drug-induced impulsivity were linked to dopamine receptor agonists like pramipexole, ropinirole, rotigotine, licensed for treating Parkinson's disease (PD) [12] and restless legs syndrome (RLS) [13,14]. More recently, the role of partial dopamine agonists like aripiprazole, brexpiprazole, cariprazine, licensed for treating psychosis and mood disorders, has also emerged as cause of drug-induced impulsivity [15]. Impulsivity as induced by PD treatment has a complex trajectory and may have a different impact on quality of life depending on underlying susceptibilities and on the occurrence of exacerbating events. The treatment might initially induce a "honeymoon period", in which patients experience heightened motivational drive and often engage in new satisfying hobbies [16]. However, impulsivity can eventually lead to pervasive behaviors and become pathologic. Even when concealed in subclinical forms [17], drug-induced impulsivity holds

the potential to significantly erode patients' QoL [18]. This erosion, appraised through metrics like the PDQ-39 scale [19], encompasses diverse neuropsychiatric and somatic domains including mobility, daily activities, stigma, social support, communication [20], urinary and sexual function, sleep, attention, and cardiovascular symptoms [21]. The impact extends beyond patients as it affects caregivers, who grapple with their own set of health issues, depression, and social impediments due to their duties of care [22].

Nevertheless, conventional evaluations focus on simple drug – physical adverse reaction associations, and often ignore neuropsychiatric symptoms, altered behavior patterns, financial hardships, and legal entanglements as emerging from drug-induced impulsivity [23], thus failing to capture the complex network of consequences of its manifestation. This underscores the crucial need for an integrative approach that consider the perspectives of both patients and caregivers and acknowledges the complex interconnections between symptoms [24], including identifying subsyndromes and exacerbating events.

In order to better characterize such networks, we can rely on databases collecting individual case safety reports of suspected ADRs from patients and healthcare professionals. In particular, in this manuscript we will rely on the US FDA Adverse Event Reporting System (FAERS), as it is global and public [25]. Crucially, the patient-produced reports offer impactful insights into the experiences and impacts of ADRs on QoL, beyond those provided by healthcare professionals [26–30].

Network analyses provide the means to explore ADRs as complex system consisting of multiple interacting entities. Specifically, they enable the analysis and visualization of ADRs as interwoven symptoms and signs [31]: a composite syndrome encompassing psychosocial implications, clustered into subsyndromes. This approach overcomes the drawbacks of viewing drug-induced impulsivity as an isolated incident. Beyond more descriptive approaches such as those built on measures of association (Ising [32],  $\Phi$  [33], and PPMI [34]), network approaches can also explore possible causal connections between symptoms, allowing to identify potential exacerbating events [35,36].

In the current manuscript we pursue three goals. First, we want to fully acknowledge the complexity of drug-induced impulsivity as reported not only by clinical researchers, but also by clinicians and patients. We go beyond a pairwise drug to adverse reaction approach and more fully embrace the idea of a syndrome of variously interconnected aspects, from behavioral addictions to their organic and psychosocial sequelae. By examining the network in which symptoms interact and affect each other, we aim to gain a deeper understanding of the impact of drug-induced impulsivity on patients' lives.

Second, we want to assess the possibility of distinct sub-syndromes within the broader spectrum of drug-induced impulsivity. For example, when impulsivity manifests as hyperphagia it may have more organic sequelae related to weight increased compared to when it manifests as pathological gambling.

Third, we assess the presence of central symptoms, potentially crucially exacerbating the syndrome of drug-induced impulsivity. By pinpointing these key symptoms, we aim to pave the way for targeted interventions that alleviate the adverse effects on patients' lives.

In pursuing these goals, our study focuses on recipients of pramipexole and aripiprazole. Pramipexole is a dopamine agonist used in neurological conditions, therefore prescribed to older individual with stronger social support and a lower baseline motivational drive. Aripiprazole is a dopamine partial agonist employed in psychiatric disorders, therefore prescribed to younger and more stigmatized individuals, with a higher baseline motivational drive. Using these two examples will allow us to capture commonalities in drug-induced impulsivity as well as potentially different mechanisms/syndromes that manifest only in a specific indication/patient type. A better understanding of the impact of these ADRs on quality of life could contribute to informed decision-making for patients and caregivers, laying the foundation for interventions capable of alleviating the toll exacted by impulsivity.

#### 2. Methods

#### 2.0 Study Design

The study design is presented in **Figure 1**. We first downloaded and pre-processed FAERS reports from January 1<sup>st</sup>, 2004, to March 31<sup>st</sup>, 2022 (Step 1) and selected cases recording impulsivity among the two separate populations of aripiprazole and pramipexole recipients (Step 2). In order to characterize the impulsivity syndrome, we identified the set of events disproportionally co-reported with drug-induced impulsivity, rather than with other suspected reactions of the same drug, using an event-event disproportionality analysis (Step 3). To explore potential sub-syndromes, we relied on three parallel commonly used descriptive network analyses and a greedy-modularity algorithm, able to identify more cohesive clusters of co-reported events (Step 4). Finally, to explore possible causal relations within these networks and the secondary impact of drug-induced impulsivity, we relied on a Bayesian network approach, able to estimate conditional probabilities of chained events (Step 5). These operations were performed in a standardized and reproducible fashion, made possible by the DiAna R package: an open access toolkit for disproportionality analyses and other pharmacovigilance investigations in the FAERS [37].




Figure 1. Pipeline of the study, showing step-by-step the study design.

## 2.1 Step 1 – Data Preprocessing

165166

167

168

169

170

We downloaded FAERS quarterly data in ASCII format (January 1<sup>st</sup>, 2004, to March 31<sup>st</sup>, 2022) [25]. Adverse events were coded according to the Medical Dictionary for

Regulatory Activities (MedDRA®, version 25.0) preferred terms (PTs) [38], while drugs

were standardized according to their active ingredients [39]. The latest report version was

173 retained, and rule-based deduplication was applied to reduce redundancy (cfr.

174 <a href="https://github.com/fusarolimichele/DiAna">https://github.com/fusarolimichele/DiAna</a>).

# 2.2 Step 2 – Case Retrieval

We retrieved aripiprazole and pramipexole recipients separately and identified cases as reports recording impulsivity among the suspected reactions. To identify impulsivity we used a MedDRA PT list specifically curated for investigating drug-induced impulsivity within the FAERS database [10], encompassing heterogenous manifestations including gambling, hypersexuality, compulsive shopping, hyperphagia, gaming, setting fires, stealing, hoarding, excessive exercise, overwork, compulsive wandering, body-focused repetitive behaviors, stereotypy, and impulsivity (see **Table S1**). MedDRA PTs used for reporting suspected ADRs do not align directly with terms in other frameworks like the Diagnostic and Statistical Manual of mental disorders (DSM-5-TR) and ICD-11 (e.g., referring to "kleptomania" as an idiopathic condition).

To explore potential risk factors for impulsivity, demographic characteristics, outcomes, and reporter contributions (e.g., healthcare practitioners, patients, lawyers) were compared between cases and non-cases within each population, using the Chi-square test for categorical and Mann-Whitney test for continuous variables. To address multiple testing, we applied the Holm-Bonferroni correction with a significance level of 0.05.

# 191 2.3 Step 3 – Disproportionality Analysis: The drug-induced impulsivity syndrome

We conducted an event-event disproportionality analysis to identify events frequently coreported with drug-induced impulsivity, separately for aripiprazole and pramipexole recipients (see **Table 1**). Disproportionate reporting was assessed using the Information Component (IC) [40], also known as pointwise mutual information (PMI) in information theory [41,42]. The IC compares the actual co-reporting of two events x (i.e., drug-induced impulsivity) and y (i.e., any specific event) with their expected co-reporting if their probability were independent (p(y,x) > p(x) \* p(y)) [41]. To mitigate the risk of false positives for infrequent events [43], a shrinkage/smoothing approach was applied by adding k=0.5 to both the numerator and denominator. Significance was determined using  $IC_{025} > 0$ .

**Table 1. 2-way contingency table.** The table shows the different instances that can be observed when considering pathologic impulsivity and a specific event. Legend: E = event; I = impulsivity; 1 = presence; 0 = lack; N = total

	Event (y)	Other events	Sum
Impulsivity (x)	$n_{I_1E_1}$	$n_{I_1E_0}$	$n_{I_1}$
Other event	$n_{I_0E_1}$	$n_{I_0E_0}$	$n_{I_0}$
Sum	$n_{E_1}$	$n_{E_0}$	N

$$IC(x,y) = PMI(x,y) = \log_2 \frac{p(y,x)}{p(x)p(y)} = \log_2 \frac{n_{I_1E_1} * N}{n_{I_1} * n_{E_1}} \approx \log_2 \frac{n_{I_1E_1} + 0.5}{\frac{n_{I_1}*n_{E_1}}{N} + 0.5}$$

$$IC(x,y)_{025} = IC - 3.3 * (n_{I_1E_1} + 0.5)^{-\frac{1}{2}} - 2 * (n_{I_1E_1} + 0.5)^{-\frac{3}{2}}$$

$$IC(x,y)_{975} = IC + 2.4 * (n_{I_1E_1} + 0.5)^{-\frac{1}{2}} - 0.5 * (n_{I_1E_1} + 0.5)^{-\frac{3}{2}}$$

# 2.4 Step 4 – Network Analysis: sub-syndromes

Building on insights from prior studies on drugs [44] and events [31,45,46] cooccurrence, our network analysis aimed to unveil, within the drug-induced impulsivity
syndrome, sub-syndromes of cohesively clustered events. Together with the Ising estimation
[32,47], already implemented in pharmacovigilance because of its ability to obtain a sparser
and easily interpretable network (because of fewer links and more definite clusters) [31], we
implemented two other more connected network estimations in order to identify broader coreporting patterns (PPMI [34], Ising,  $\phi$  [33]). See **Table 2** for the features of the three
networks. We did not consider negative links (i.e., potential mutually exclusive events).

**Table 2. Network estimations.** The table shows the features of the network estimations implemented.

Ising	PPMI	PHI	
	(positive pointwise mutual information)		
The Ising model computed partial	Focuses on cases where events	The $\phi$ coefficient, akin to the traditional	
logistic regression coefficients $(\beta)$	were reported together (n <sub>11</sub> ), applying	correlation coefficient, approaches one when	
considering the impact of all other events.	additive smoothing (k=1, d=N° events).	two events are frequently reported together	
Positive coefficients indicated a tendency for	Bootstrap and Bonferroni adjustments	and converges to zero if they are either	
two events to be reported together. A	assessed statistical significance, with a	independent or mutually exclusive. The	
LASSO method pruned out weak links,	0.01 threshold for higher specificity.	Bonferroni adjustment was applied with a	
eliminating spurious associations but	Gives more weight to associations with	significance threshold of 0.01. The p-value	
potentially sacrificing weaker genuine	infrequent events.	was computed using a χ <sup>2</sup> probability	
relationships, especially triangular type		distribution with one degree of freedom.	
interactions.			
$Ising_{x,y} = max\left(\frac{1}{2}\beta_{x,y}\beta_{y,x},0\right)$	$PPM I_{x,y} = \max \left( log_2 \frac{(n_{11} + k) \times (N + kd)}{(n_{1*} + k) \times (n_{*1} + k)}, 0 \right)$	$\phi_{x,y} = max \left( \frac{n_{11}n_{00} - n_{10}n_{01}}{\sqrt{n_{1*}n_{0*}n_{*1}n_{*0}}}, 0 \right)$	

Separately for the two population of aripiprazole and pramipexole recipients, the three networks shared identical nodes by definition but different links were inferred due to the different properties of the algorithms. We used modularity maximization [48] and the greedy modularity algorithm [49] to detect clusters of co-reported signs and symptoms. Between networks we compared degree of link overlap (Jaccard similarity index [50]), goodness of partitioning (clustering modularity); cluster agreement (Purity index [51–53]), link density (ratio of actual links to possible links), and interconnectedness among neighbors (small worldness [54]).

- 2.5 Step 5 Bayesian Network: The secondary impact of drug-induced impulsivity
- While other methods look only at symmetrical associations, we expect that some events may cause other events. To exploratively identify these potential causal dependencies following
- drug-induced impulsivity, we estimated the conditional probabilities of chained events
- 228 [35,36]. The resulting Bayesian network is both directed, offering insights into plausible
- 229 causal relationships, and acyclic (no chain of arrows loops back to itself). The network was
- derived through 1000 bootstraps, optimizing the BIC score with the Hill-Climbing algorithm.
- We computed the average network retaining links exceeding a threshold computed via  $L_1$
- 232 minimization. Evaluation focused on nodes with the highest out-degree centrality and the
- 233 main manifestations of drug-induced impulsivity.
- 235 3. Results

216

217

218

219

220

221


222

223

224

- 236 3.1 Case Retrieval
- We retrieved 12,030,756 distinct reports: 27,601 pramipexole recipients and 80,238
- 238 aripiprazole recipients. Suspected drug-induced impulsivity was documented in 7.49% of
- 239 pramipexole recipients (n=2,066: mainly gambling disorder-n=1,345; 4.87%-,
- 240 hypersexuality-612; 2.22%-, impulsivity-453; 1.64%-, compulsive shopping-384; 1.39%-,
- and hyperphagia-334; 1.21%-) and in 4.50% aripiprazole recipients (n=3,609: mainly
- 242 gambling disorder-n=2,067; 2.58%-, hypersexuality-1,077; 1.34%-, compulsive shopping-
- 243 1.029; 1.28%, hyperphagia-868; 1.08%, and impulsivity-730; 0.91%) (see **Table S2**).
- Among pramipexole recipients, drug-induced impulsivity was more frequently
- 245 reported in males (57.42% vs. 36.99%, p<0.001) and younger patients (56 vs. 67, p<0.001),
- often recording non-serious outcomes (i.e., no death, disability, or hospitalization; 44.87% vs.
- 247 33.58%, p<0.001) and Parkinson's Disease (PD) as indication (see **Figure 2** and **Table S3**).
- 248 Similarly, among aripiprazole recipients, drug-induced impulsivity was more common in

males (48.59% vs. 40.72%, p<0.001); peculiarly, hospitalization was more common (33.39% vs. 23.39%, p<0.001), and an important portion of reports was submitted by lawyers (34.08% vs. 1.10%, p<0.001) (see **Table S4**).




**Figure 2** – **Characteristics of the investigated populations.** The figure presents information about two populations extracted from the deduplicated FAERS database - one consisting of reports related to pramipexole and the other consisting of reports related to aripiprazole. Within these populations, cases of pathologic impulsivity were identified. The figure compares drug-induced impulsivity cases and the reference group (other reports recording the drug), considering the indication for use. Only the two most prevalent indications were taken into account. For each drug and indication, the caption describes the percentage of reports with the specified indication, the percent of reports involving males, and the median and interquartile range of ages. In the drug-induced impulsivity cases sections, green and red arrows indicate variables that are respectively higher or lower than expected based on the reference group.

3.2 Disproportionality Analysis: the drug-induced impulsivity syndrome

A total of 56 events were disproportionally reported with pramipexole-related impulsivity. The highest IC was found for obsessive-compulsive disorder (OCD, reporting rate = 26.77%; IC median = 3.47, 95%CI = 3.33-3.57), emotional distress (21.35%; 3.42, 3.26-3.54), marital problem (1.11%; 3.30, 2.61-3.79), dependence (2.37%; 3.26, 2.79-3.6), economic problems (6.05%; 3.15, 2.85-3.36), compulsions (1.74%; 3.05, 2.49-3.44), fear (4.65%; 2.95, 2.61-3.19), eating disorder (2.47%; 2.95, 2.49-3.28), personality change (2.66%; 2.93, 2.49-3.26), and suicide attempt (5.28%; 2.74, 2.43-2.97).

A total of 107 events were disproportionally reported with aripiprazole-related impulsivity. The highest IC was found for bankruptcy (10.58%; 4.43, 4.26-4.55), divorce (7.59%; 4.38, 4.19-4.53), homeless (6.93%; 4.37, 4.16-4.52), shoplifting (5.02%; 4.37, 4.12-4.54), neuropsychiatric symptoms (4.74%; 4.35, 4.1-4.53), loss of employment (12.64%; 4.33, 4.18-4.44), theft (5.79%; 4.32, 4.09-4.48), economic problems (37.85%; 4.28, 4.19-4.34), sexually transmitted disease (3.05%; 4.24, 3.93-4.47), and OCD (33.19%; 4.16, 4.07-4.23) (see Figure 3 and Table S5 and S6).



**Figure 3** – **Secondary impact of drug-induced impulsivity.** The dendrogram shows the events disproportionally reported with aripiprazole and pramipexole-related impulsivity. Events are gathered by clinical similarity in alternately colored slices, labeled on the outer border with a name and an icon. Disproportionalities are shown as dots organized in two colored rings, each representing a drug/case population. The dots' size is proportional to the percent of reports showing the event, the color is darker for stronger disproportionality (higher median Information Component).

#### 3.3 Network Analysis and sub-syndromes

In the second step we estimated the networks using three different approaches and identifying clusters of events. We included a total of 120 nodes (107 events disproportionally reported with impulsivity + 13 impulsivity PTs) and 70 nodes (56 + 14) for the aripiprazole and pramipexole network, respectively. Although the nodes remained constant, edges, clusters, and network properties were different in the three mathematical representations (**Table 3, S7, S10-S11, Figure S1-S8, S11-S16**). As expected, the degree centrality was highest for the

most common events in Ising and for the rarest in PPMI. The Jaccard similarity was highest between the networks estimated by Ising and  $\phi$  and lowest for the networks estimated by  $\phi$ and PPMI (half of the links being different). The clustering was most overlapping between  $\phi$ -PPMI, followed by  $\phi$ -Ising and PPMI-Ising, as captured by the purity index.  $\phi$  and PPMI tended to present clusters including multiple clusters from the Ising estimated network (Figures S11-S16).

Table 3. Network properties. The table shows the network properties for the three networks estimated for aripiprazole and pramipexole, respectively, and for their comparison. Legend: (-) means that there is also a strong link between the first and last element.

	Aripipraz	ole (120 nodes)	
gambling di	sorder (N=2057), economic probl		sive disorders (1198)
	Ising	$\phi$	PPMI
Links	301	1186	1254
Central node (1°)	economic problems	Irritability	overwork
Heaviest links (1-3°)	AP below therapeutic – effect	(–)AP below therapeutic–	Kleptomania-overwork-
	variable – effect incomplete	effect variable-toxicity(-)	pyromania
	Theft-shoplifting		Overwork-poriomania
Clusters (N)	10	5	4
Clustering modularity	0.71	0.59	0.46
Small worldness $(\omega)$	0.26	0.04	0.03
	$\phi$ -Ising	$\phi$ -PPMI	PPMI-Ising
Jaccard (out of max)†	0.25 (0.25)	0.56 (0.95)	0.21 (0.24)
Purity index‡	0.68	0.89	0.59
	Pramipex	<b>cole</b> (70 nodes)	
gambling	disorder (N=1340), obsessive-con	npulsive disorders (553), and hy	ypersexuality (543)
	Ising	$\phi$	PPMI
Links (density %)	85	240	576
Central node (1°)	gambling disorder	mental disorder	pyromania
Heaviest links (1-3°)	body-focused disorders-	Pain-emotional distress-	(–)Poriomania–pyromania–
	kleptomania	obsessive-compulsive	gaming disorder(-)
	mental impairment-mental	disorder	
	disorder	Hyperphagia-weight	
	on and off phenomenon— dyskinesia	increased	
Clusters (N)	10	6	4
Clustering modularity	0.66	0.51	0.15
Small worldness (ω) §	-0.01	0.29	0.47
	$\phi$ -Ising	$\phi$ -PPMI	PPMI-Ising
Jaccard (out of max)	0.34 (0.35)	0.23 (0.42)	0.12 (0.15)
Purity index	0.44	0.66	0.39

<sup>300</sup> 

302 303

304 305

306

291 292

293

294

295

296

297

298

299

†  $(J(A, B) = \frac{|A \cap B|}{|A \cup B|})$ . ‡  $Purity = \frac{1}{N} \sum_{k=1}^{K_{min}} \max_{\pi} n_{k,\pi}$ , with  $K_{min}$  the minimum clusters and  $\max_{\pi} n_{k,\pi}$  the maximum elements. § a small world has  $\omega = \frac{L_r}{L} - \frac{c}{C_l} \approx 0$ : the shortest path length L is similar to that of an equivalent random network r and the

clustering coefficient C is similar to that of an equivalent lattice network l.

The three representations were considered as three different perspectives on the same phenomenon and composed into a single visualization for each population (Figure 4, 5). For

<sup>301</sup> 

# a detailed description of the identified clusters, contextualized within the existing literature, see the discussion (paragraph 4.4).




Figure 4. The secondary impact of aripiprazole-induced impulsivity. The network shows the events disproportionally reported with aripiprazole-related impulsivity and their pattern of co-reporting. Drug-induced impulsivity manifestations are shown as squares and other events as circles. Node colors identify clusters from the Ising estimation, dashed contours for the estimation, and colored contours for the PPMI estimation. The link width represents the weight of the links of the Ising, here chosen over the others because they are fewer and more conservative. The layout has been manually adjusted to reduce the overlapping. The layout calculated using a spring model with, as weight, the weights from the individual networks and the average of the weights of the three networks, after rescaling them from 0 to 1, is shown in the supplementary material.




Figure 5. The secondary impact of pramipexole-induced impulsivity. The network shows the events disproportionally reported with pramipexole-related impulsivity and their pattern of co-reporting. Drug-induced impulsivity manifestations are shown as squares and other events as circles. Node colors identify clusters from the Ising estimation, dashed contours for the estimation, and colored contours for the PPMI estimation. The link width represents the weight of the links of the Ising, here chosen over the others because they are fewer and more conservative. The layout has been manually adjusted to reduce the overlapping. The layout calculated using a spring model with, as weight, the weights from the individual networks and the average of the weights of the three networks, after rescaling them from 0 to 1, is shown in the supplementary material.

# 3.4 Bayesian Network: The secondary impact of drug-induced impulsivity

The Bayesian Network yielded insights into the directional associations between co-reported events (see **Figure 6** and OSF repository [55]). High out-degree centrality identified pivotal events that likely heightened the likelihood of reporting other events (Figure S9-S10). Since this directed network only generates hypotheses, we preferred temporal terminology (i.e., preceding and following) to causal terminology even if no data on actual temporal sequences was included in the analyses.




Figure 6. The secondary impact of the main drug-induced impulsivity, aripiprazole and pramipexole. The ego-networks extracted from the Bayesian Network show the potential direction of the co-reporting relationships between the events, thus providing insight into the direct and indirect impact of drug-induced impulsivity. Nodes linked to hyperphagia, hypersexuality, pathological gambling, and compulsive shopping are represented. Only out-neighbors of order equal or less than 1 are shown here, together with out-neighbors of order 2 considered relevant for clinical interpretation.

In pramipexole recipients, anxiety (3.55), emotional distress (2.92), and gambling (2.30) attained the highest out-degree centrality. Anxiety preceded insomnia (with irritability, somnolence, and attention disturbances), stress and depression (with suicide), fear, OCD, and emotional distress. Emotional distress preceded pain and injury (with major depression and economic problems), abnormal thinking and behavior, weight gain, and pathologic gambling.

- 345 Furthermore, hypersexuality preceded delusional jealousy and marital difficulties,
- 346 compulsive shopping stealing behaviors, and hyperphagia weight increase.
- 347 In aripiprazole recipients, economic problems (5.97), gambling (4.15), and hyperphagia
- 348 (2.33) attained the highest out-degree centrality. Economic problems preceded theft,
- 349 hoarding, divorce, loss of employment, homelessness, suicide, sex dysfunction, sexually
- transmitted diseases, and eating disorder. Gambling preceded aggressivity, suicide, cognitive
- disorders, hyperphagia, and paraphilia. Hyperphagia preceded somnolence and fatigue (with
- stress, attention disturbances, myalgia, cough), hunger, weight increase (with constipation),
- 353 obesity (with hypertension), compulsive wandering, and paraphilic disorders. Anxiety
- 354 preceded depression (with sleep disorders and suicide), fear and panic attacks (with
- 355 relationship issues), pain and injury (with emotional distress, disability, anhedonia, and
- 356 economic problems). Hypersexuality preceded sexual dysfunction, sexually transmitted
- diseases, unintended pregnancy, and loss of employment. Compulsive shopping preceded
- as eating disorders and economic problems.

#### 4. Discussion

359

- 361 4.1 Summary and Key Results
- 362 We investigated aripiprazole and pramipexole reports to capture the syndromes and sub-
- 363 syndromes related to drug-induced impulsivity.
- The event-event disproportionality analysis revealed signs and symptoms commonly reported
- alongside impulsivity, thus delineating an impulsivity syndrome, separately for aripiprazole
- and pramipexole recipients. The impulsivity syndrome encompassed mainly psychosocial
- events but also organic conditions.
- 368 The network analysis identified meaningful clusters, such as delusional jealousy (also known
- as Othello syndrome [56]) and dopamine dysregulation syndrome (i.e., the excessive use of
- 370 levodopa) in pramipexole recipients, and obesity-hypoventilation syndrome (historically
- Pickwickian syndrome) and social issues in aripiprazole recipients. In particular, employing
- more sensitive network analyses like Phi and PPMI generated more interconnected networks,
- which identified potential macro-clusters combining several smaller clusters identified by the
- 374 Ising model.
- 375 Crucially, potential causal mechanisms and secondary consequences of drug-induced
- impulsivity can be highlighted by Bayesian Network methods, providing targets for potential
- 377 interventions. Anxiety and economic problems emerged as pivotal events that could be
- potentially targeted to disrupt the chain of events and alleviate the burden of drug-induced

- 379 impulsivity: for instance, monitoring and effectively managing anxiety or providing financial
- 380 guidance or legal guardianship to prevent wasteful spending. Since marital problems affect
- caregivers' QoL and increase the risk of early placement in nursing homes [22], addressing
- delusional jealousy and economic problems, identified as factors preceding marital problems,
- may be critical for preserving wellbeing in pramipexole recipients.
- 384 In order to better contextualize and qualify these findings, we now discuss in detail the results
- 385 of case retrieval, disproportionality analysis, network analysis, Bayesian network, and the
- 386 limits and conclusions of the study.
- 387 4.2 Case Retrieval
- 388 Our findings align with established risk factors, including male gender and younger age
- 389 [57,58], Parkinson's Disease (PD) [59,60] and depression [61]. Commonly reported
- 390 impulsivity manifestations included the "four knights"[9] (i.e., gambling, shopping,
- 391 hyperphagia, and hypersexuality), garnering special attention due to their pronounced impact
- 392 on QoL. Other manifestations were body-focused repetitive behaviors, paraphilic disorders,
- and hoarding.
- 394 4.3 Disproportionality analysis: the drug-induced impulsivity syndrome
- 395 By performing the event-event disproportionality analysis within each drug population
- 396 separately, comparing reports involving impulsivity with those encompassing various
- reactions other than impulsivity to the same drug, we addressed indication bias and other
- 398 confounding factors. This comparative analysis served as a rigorous filter, allowing us to sift
- through the complex data and unveil the genuine characteristics associated with impulsivity,
- 400 as well as those arising from the dynamic interaction between impulsivity and the underlying
- 401 drug or disease, excluding traits tied solely to the underlying drug or disease.
- This approach revealed a complex syndrome, characterized by psychosocial, cognitive,
- 403 psychosomatic, and metabolic events. The syndromes identified for impulsivity within
- 404 pramipexole and aripiprazole recipients differ significantly. Multiple factors may contribute
- 405 to the seemingly higher burden on QoL observed with aripiprazole-induced impulsivity, with
- 406 functional (or psychosomatic) manifestations and social issues impacting work, relationships,
- 407 and economics. Pramipexole is primarily administered to older patients with
- 408 hypodopaminergic conditions, characterized by motor impairment and reduced motivational
- drive. These patients, well managed and supported by caregivers because of the later onset
- 410 and clear neurologic origin of the disease, may experience a mitigated drug-induced
- 411 impulsivity burden. Conversely, aripiprazole is prescribed to younger patients with mood and
- psychotic disorders, often linked to hyperdopaminergic states and a pre-existing diathesis for

impulsivity. Challenges for caregivers and social support are heightened in these cases due to earlier onset, psychiatric origins, and stigma, potentially leading to a greater burden. Further, over a third of aripiprazole cases were submitted by lawyers. This may be explained either by a potentially malicious overreporting for legal compensation (cfr., Abilify lawsuit) [62] or by a reaction to underdiagnosis by physicians, who may be hesitant to attribute behavioral changes to the medication when underlying psychiatric conditions are present. In reports filed by lawyers, the desire to win legal compensation may have prompted more detailed descriptions of the impact of impulsivity on QoL, or possibly even exaggerated the impact, thus contributing to the observed differences between the two drugs. Intriguingly, there could also be an ascertainment bias, as neurologists prescribing pramipexole may be less aware of psychiatric issues compared to psychiatrists prescribing aripiprazole.

# 4.4 Network Analysis: sub-syndromes

Network analysis in pharmacovigilance, complementary to other unsupervised approaches such as vigiGroup [63], is a promising tool to detect potential syndromes and subsyndromes, to help the characterization of signals. Employing three estimation methods, the network analysis revealed potential subsyndromes associated with specific impulsivity expressions in the two populations (**Figure 7**). The Ising delineated well-defined clusters, while PPMI and  $\phi$  emphasized inter-clusters relationships.




Figure 7. Drug-induced impulsivity syndrome, aripiprazole and pramipexole. The main syndrome, representing one or more strongly interconnected central clusters of symptoms and signs identified through network analysis, is depicted as the central figure. Other potential sub-syndromes are shown on the sides highlighted with a colored square.

By incorporating various expressions of impulsivity, we anticipated that the central cluster would encompass the key features of impulsivity regardless of its form, whether they act as risk factors or consequences of impulsivity. In both populations, cognitive and mood disorders (e.g., cognitive and memory impairment, bipolar disorder, depression) were included in the central cluster. Notably, they have been recorded as frequently associated with drug-induced impulsivity and contributing to disability development [64]. Obesity-hypoventilation syndrome [65], involving weight gain, cognitive and sleep disorders, and sedation, was consistent in both populations but seemingly heavier in aripiprazole recipients, which also reported obesity, sleep apnoea syndrome, hypertension, and metabolic blood alterations (increased lipids, transaminases, and glucose in the blood), supporting the observed link between hyperphagia and diabetes onset [66].

For aripiprazole recipients (Figure 4), the central cluster also included panic attack and auditory hallucinations, sleep disorders, decreased appetite, and stress. Stress was further connected to a psychosomatic sub-syndrome involving irritability, migraine, back and

abdominal pain, reflux, diarrhoea, constipation, and hyperidrosis. Gambling and shopping were linked to pervasive social issues (hoarding, unemployment, homeless, bankruptcy, divorce), theft, and suicidal ideation and attempts (already observed during hyperdopaminergic impulsive states [67]). Hypersexuality was linked to unintended pregnancy, sexually transmitted diseases, and sexual dysfunction.

Among pramipexole recipients (Figure 5), the central cluster also included apathy, delusion, and economic problems. The dopamine dysregulation sub-syndrome (a manifestation of pathological impulsivity marked by excessive levodopa use [68–70], co-administered with dopamine agonists to better control motor symptoms), involved on and off phenomenon (oscillations in effectiveness and motor and motivational symptoms), excessive levodopa use to avoid off phases, and dopamine agonist withdrawal syndromes (DAWS) upon discontinuation [71]. A cluster aligned with paranoid delusional jealousy (false and unwavering belief in the partner's unfaithfulness), often seen in PD with drug-induced hypersexuality [72] and here characterized by delusional jealousy, hallucinations, irritability, crying, and marital problems. Notably, marital problems have been associated with early placement in nursing homes and worse prognosis [73]. We also found a cluster with fear, pain, stress, anxiety, depression, and suicidal ideation, indicative of the transformation of reward-driven impulsivity into stressful risk-averting compulsivity over time [74]. Finally, the co-reporting of two archetypal compulsive symptoms—body-focused repetitive behaviors and stealing behaviors—was evident.

#### 4.5 Bayesian Network: the secondary impact of drug-induced impulsivity

This interplay of events within the context of drug-induced impulsivity is intricate and multifaceted. Events reported alongside drug-induced impulsivity may result from impulsivity itself (like financial problems from gambling) or predispose individuals to impulsivity (e.g., bipolar disorder). Sometimes, events can both trigger and be exacerbated by drug-induced impulsivity (e.g., anxiety [75,76]). Sometimes events are concomitantly mentioned for precision, such as in cases of semantic overlap (e.g., theft and shoplifting, or injury and brain injury). Events associated with drug-induced impulsivity may even be synonyms for well-known impulsivity expressions (e.g., restlessness, referring to excessive wandering and poriomani), or could be the very reason for prescribing the drug, as seen in the off-label use of aripiprazole to prevent behavioral and cognitive decline in brain injury [77] or to address drug dependence [78,79]. In order to get insights into potential directional associations to attempt the formulation about clinically plausible causal sequences, we implemented a Bayesian Network. Anxiety emerged as a central factor, preceding insomnia,

irritability, cognitive impairment, stress, injury, pain (linked to disability and economic problems), depression, and even suicidal ideation. Drug-induced impulsivity manifestations appeared to exacerbate each other. Economic problems had the highest out-degree centrality among aripiprazole recipients, preceding theft, relationship difficulties, and suicidal ideation. The Bayesian Network provides clinicians with valuable insights on the pivotal nodes that could be targeted by interventions to disrupt the cascade of events and ameliorate the secondary impact of drug-induced impulsivity. It also highlighted secondary ramifications of main impulsivity manifestations: hypersexuality precedes marital problems through delusional jealousy in pramipexole recipients, while it precedes unintended pregnancy and sexually transmitted diseases in aripiprazole recipients; hyperphagia precedes weight increase in pramipexole recipients and obesity, somnolence, and cognitive impairment in aripiprazole. Marital problems, following delusional jealousy and economic problems in pramipexole recipients, may be of particular interest since they are associated with an early placement in nursing homes [73]. Finally, the Bayesian Network seems to support the higher secondary impact of drug-induced impulsivity in aripiprazole recipients.

## 4.6 Limitations and Further Developments

- While this study provides valuable insights into the intricate interplay of events related to
- drug-induced impulsivity and its subsequent implications, it is crucial to acknowledge its
- 502 limitations.

- 503 Spontaneous reports, while uniquely granting access to patients' perspective, are susceptible
- 504 to biases like under-reporting, missing data, and unverified reliability, preventing reliable
- incidence or prevalence estimates. The high contribution of reports from lawyers may have
- 506 influenced the higher psychosocial impact attributed to aripiprazole-induced impulsivity.
- Nonetheless, this study sets the foundation for further studies and a potential score to assess
- the impact of ADRs on QoL.

Limitations in network analysis methodologies adopted include the Ising estimation's assumptions (pairwise interaction, linear effects, and binary variables), and the inability to account for time and severity in symptom manifestation. The incorporation of negative links could facilitate a more nuanced separation of symptoms that infrequently co-occur. The Bayesian Network lacks bidirectional relationships and cyclic feedback loops and would require the inclusion of all shared causes between any two events (causal Markov condition) to achieve its full capacity to illuminate causality. These limitations could be rectified by integrating clinical longitudinal data and embedding temporal aspects into the network analysis.

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

Looking ahead, a broader definition of drug-induced impulsivity could improve sensitivity in case retrieval. Conditions like suicide attempts, hypersomnia, obsessivecompulsive symptoms, explosive anger, personality changes, disturbance in attention, and drug dependence might represent different expressions of this underdefined condition, warranting further exploration [10,70]. 4.7 Conclusion The profound impact of drug-induced impulsivity reverberates across patients and their families, encompassing psychosocial challenges and organic complications such as metabolic syndrome (in the case of hyperphagia), and sexual health issues (in the case of hypersexuality). Recognizing these potential consequences is crucial for informed pharmacological management and diligent patient monitoring. Network analysis has revealed intriguing co-reporting patterns among adverse events, leading to their classification as subsyndromes. Notable examples include the emergency of obesity-hypoventilation syndrome with hyperphagia and associations of hypersexuality with delusional jealousy in pramipexole recipients and unintended pregnancy and sexually transmitted diseases in aripiprazole recipients. Our parallel approach effectively avoids the risk of disease-related diathesis compromising analytical integrity, enhancing the robustness of our findings. For clinicians, this study emphasizes the potential burden of drug-induced impulsivity, and therefore the necessity of meticulous scrutiny into patients' medical histories. Factors such as age, gender, pre-existing mood disorders and family history should be red flags, warranting heightened vigilance. While transitioning to an alternative active ingredient may mitigate impulsivity, it is not always feasible or adequate. Monitoring for potential complications, as unveiled in our work (e.g., obesity-hypoventilation syndrome and delusional jealousy), is pivotal when such transitions are not a viable solution. For example, an overlooked delusional jealousy may result in marital problems and early nursing home placement. Central to our findings is the pivotal realization that drug reactions rarely occur in isolation; instead, they manifest as syndromes with diverse signs and symptoms. These can be direct reactions to the drug itself, secondary consequences to the reaction, risk factors for the reaction, or comorbidities. Causal chains and loops can contribute to symptom aggravation and chronicity. Identifying syndromes and sub-syndromes, combining network strategies with traditional techniques and clinical judgment, proves a potent strategy for delving into the secondary impact of adverse drug reactions and fostering heightened awareness within clinical practice.

- In sum, the intricate relationships between signs and symptoms, coupled with the insights
- from the Bayesian Network, underscore the multifaceted nature of drug-induced impulsivity.
- More significantly, it equips research, and secondarily clinicians, with indispensable tools to
- 554 identify potential intervention points, decipher causal sequences, and mitigate the cascading
- 555 secondary effects associated with drug-induced impulsivity. In doing so, this study
- 556 contributes to advancing our comprehension and management of drug-induced impulsivity,
- ultimately enhancing the well-being and care of affected patients.
- 559 Acknowledgements

564

- MedDRA®, version 25.0 was developed under the auspices of the International Council for
- Harmonization of Technical Requirements for Pharmaceuticals for Human Use.
- Part of the work was presented orally at the SIF congress, 2023, in Rome.
- Icons for figures 1, 2, 6, and 7 were obtained using Bing Image Creator.
- 565 Declarations
- **Funding**: No specific funding supported this research.
- 567 Conflicts of interest: The authors declare no conflict of interest specific for this research.
- 568 Ethics approval: not applicable because spontaneous reports of the FAERS are anonymous and
- publicly available.
- 570 Consent to participate: not applicable because spontaneous reports of the FAERS are anonymous
- and publicly available.
- 572 Consent for publication: not applicable because spontaneous reports of the FAERS are anonymous
- and publicly available.
- 574 Software used: Analyses were performed using R (version 4.2.1)[80] and Python (version 3.8.16
- 575 )[81]. We relied on several essential packages for network analysis: *IsingFit*[47], *igraph*[82],
- 576 *psych*[83], and *bnlearn*[35].
- 577 Availability of data and material: The data we used comes from the FDA Adverse Event Reporting
- 578 System (FAERS), and is made publicly available by the FDA as quarterly data downloadable at
- 579 <a href="https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html">https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html</a>. The algorithm for cleaning
- 580 FAERS data is open-source at <a href="https://github.com/fusarolimichele/DiAna">https://github.com/fusarolimichele/DiAna</a>, and the cleaned database is
- available on an OSF repository[84] and through the R package DiAna[85].
- Code availability: The code for the project is available on an OSF repository[55], the function for the
- Ising network is also available in the DiAna package (cfr. "network\_analysis()")[85].

**Author contributions:** MF, SP, LM, conceptualized and designed the study. MF, SP, LM developed the methodology. The formal analysis was performed by MF, SP, LM, VG. MF, SP, VG performed the visualization. MF, SP, LM, VG wrote the original draft. All the authors strongly contributed to the interpretation of results, and to the review and editing of the draft. All the authors read and approved the final version.

- References
- 592 1. Engel GL. The need for a new medical model: a challenge for biomedicine. Science.
- 593 1977;196:129–36.
- 594 2. Young A. The Anthropologies of Illness and Sickness. Annu Rev Anthropol. 1982;11:257–
- 595 85.

- 3. Kleinman A, Eisenberg L, Good B. Culture, illness, and care: clinical lessons from
- anthropologic and cross-cultural research. Ann Intern Med. 1978;88:251–8.
- 4. Lorimer S, Cox A, Langford NJ. A patient's perspective: the impact of adverse drug
- reactions on patients and their views on reporting. J Clin Pharm Ther. 2012;37:148–52.
- 5. Suh D-C, Woodall BS, Shin S-K, Santis ERH-D. Clinical and Economic Impact of
- Adverse Drug Reactions in Hospitalized Patients. Ann Pharmacother. 2000;34:1373–9.
- 602 6. Rolfes L, van Hunsel F, Taxis K, van Puijenbroek E. The Impact of Experiencing Adverse
- Drug Reactions on the Patient's Quality of Life: A Retrospective Cross-Sectional Study in
- 604 the Netherlands. Drug Saf. 2016;39:769–76.
- 7. Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT, et al. Guidelines
- 606 for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO
- 607 Extension. JAMA. 2018;319:483–94.
- 8. Haag S, Junge L, Lotz F, McGauran N, Paulides M, Potthast R, et al. Results on patient-
- reported outcomes are underreported in summaries of product characteristics for new drugs. J
- 610 Patient-Rep Outcomes. 2021;5:127.
- 611 9. Weintraub D. Impulse control disorders in Parkinson's disease: A 20-year odyssey. Mov
- 612 Disord Off J Mov Disord Soc. 2019;34:447–52.
- 10. Fusaroli M, Raschi E, Contin M, Sambati L, Menchetti M, Fioritti A, et al. Impulsive
- 614 Conditions in Parkinson's Disease: a pharmacosurveillance-supported list. Parkinsonism
- 615 Relat Disord. 2021;90:79–83.
- 616 11. Fusaroli M, Pellegrini L, Fusaroli R, Raschi E, Menchetti M, Poluzzi E. Behavioral
- excess and disruptive conduct: a historical and taxonomical approach to the origin of the
- 618 "Impulse Control Disorders" diagnostic construct. Addiction [Internet]. 2022 [cited 2022 Nov
- 619 21];n/a. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/add.16086
- 620 12. Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E,
- et al. Dopamine Agonists and Impulse Control Disorders: A Complex Association. Drug Saf.
- 622 2018;41:19–75.
- 13. Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling
- 624 in patients with restless legs syndrome treated with dopaminergic agonists. Neurology.
- 625 2007;68:301–3.
- 626 14. Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse
- 627 Control Disorders with the use of Dopaminergic Agents in Restless Legs Syndrome: a Case-
- 628 Control Study. Sleep. 2010;33:81–7.

- 629 15. Fusaroli M, Raschi E, Giunchi V, Menchetti M, Rimondini Giorgini R, De Ponti F, et al.
- 630 Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-
- 631 Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System. Int J
- 632 Neuropsychopharmacol. 2022;25:727–36.
- 633 16. Béreau M, Fleury V, Bouthour W, Castrioto A, Lhommée E, Krack P.
- Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review. Rev Neurol
- 635 (Paris). 2018;174:653–63.
- 17. Jeyadevan A, Bakeberg M, Byrnes M, Kenna J, McGregor S, Ghosh S, et al. Quality of
- 637 life implications for elevated trait impulsivity in people with Parkinson's disease. Qual Life
- 638 Res. 2023;32:1143–50.
- 18. Leplow B, Renftle D, Thomas M, Michaelis K, Solbrig S, Maetzler W, et al.
- 640 Characteristics of behavioural addiction in Parkinson's disease patients with self-reported
- impulse control disorder and controls matched for levodopa equivalent dose: a matched case—
- 642 control study. J Neural Transm. 2023;130:125–33.
- 643 19. Phu AL, Xu Z, Brakoulias V, Mahant N, Fung VSC, Moore GD, et al. Effect of impulse
- control disorders on disability and quality of life in Parkinson's disease patients. J Clin
- 645 Neurosci. 2014;21:63-6.
- 20. Skorvanek M, Rosenberger J, Minar M, Grofik M, Han V, Groothoff JW, et al.
- Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in
- patients with Parkinson's disease. J Neurol Sci. 2015;353:87–91.
- 21. Jesús S, Labrador-Espinosa MA, Adarmes AD, Méndel-Del Barrio C, Martínez-Castrillo
- 650 JC, Alonso-Cánovas A, et al. Non-motor symptom burden in patients with Parkinson's
- disease with impulse control disorders and compulsive behaviours: results from the
- 652 COPPADIS cohort. Sci Rep. 2020;10:16893.
- 22. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in parkinson's
- disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism
- 655 Relat Disord. 2006;12:35–41.
- 656 23. Antonini A, Barone P, Bonuccelli U, Annoni K, Asgharnejad M, Stanzione P. ICARUS
- 657 study: prevalence and clinical features of impulse control disorders in Parkinson's disease. J
- Neurol Neurosurg Psychiatry. 2017;88:317–24.
- 659 24. Castillon G, Salvo F, Moride Y. The Social Impact of Suspected Adverse Drug
- 660 Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database. Drug Saf.
- 661 2019;42:27–34.
- 25. FAERS Quarterly Data Extract Files [Internet]. [cited 2022 Dec 24]. Available from:
- 663 https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html
- 664 26. Härmark L, van Hunsel F, Grundmark B. ADR Reporting by the General Public: Lessons
- Learnt from the Dutch and Swedish Systems. Drug Saf. 2015;38:337–47.
- 666 27. Härmark L, Raine J, Leufkens H, Edwards IR, Moretti U, Sarinic VM, et al. Patient-
- 667 Reported Safety Information: A Renaissance of Pharmacovigilance? Drug Saf. 2016;39:883–
- 668 90.

- 28. Inácio P, Cavaco A, Airaksinen M. The value of patient reporting to the
- pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83:227–46.
- 671 29. Rolfes L, van Hunsel F, Wilkes S, van Grootheest K, van Puijenbroek E. Adverse drug
- reaction reports of patients and healthcare professionals-differences in reported information.
- 673 Pharmacoepidemiol Drug Saf. 2015;24:152–8.
- 674 30. Watson S, Chandler RE, Taavola H, Härmark L, Grundmark B, Zekarias A, et al. Safety
- 675 Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop
- using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre. Drug
- 677 Saf. 2018;41:203–12.
- 31. Fusaroli M, Raschi E, Gatti M, De Ponti F, Poluzzi E. Development of a Network-Based
- 679 Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting
- 680 System. Front Pharmacol. 2021;12:3542.
- 681 32. Epskamp S, Borsboom D, Fried EI. Estimating psychological networks and their
- accuracy: A tutorial paper. Behav Res Methods. 2018;50:195–212.
- 683 33. Yule GU. On the Methods of Measuring Association Between Two Attributes. J R Stat
- 684 Soc. 1912;75:579–652.
- 685 34. Chen SF, Goodman J. An empirical study of smoothing techniques for language
- 686 modeling. Proc 34th Annu Meet Assoc Comput Linguist [Internet]. USA: Association for
- 687 Computational Linguistics; 1996 [cited 2023 Mar 17]. p. 310–8. Available from:
- 688 https://doi.org/10.3115/981863.981904
- 689 35. Scutari M. Learning Bayesian Networks with the bnlearn R Package. J Stat Softw.
- 690 2010;35:1–22.
- 691 36. Briganti G, Scutari M, McNally RJ. A tutorial on Bayesian Networks for
- 692 psychopathology researchers [Internet]. OSF; 2021 [cited 2024 Mar 31]. Available from:
- 693 https://osf.io/h4vxa
- 694 37. Fusaroli M, Giunchi V. DiAna. An open access toolkit for DIsproportionality ANAlysis
- and other pharmacovigilance investigations in the FAERS. [Internet]. 2024. Available from:
- 696 https://github.com/fusarolimichele/DiAna\_package
- 697 38. MedDRA [Internet]. [cited 2023 Feb 4]. Available from: https://www.meddra.org/
- 698 39. Fusaroli M, Giunchi V, Battini V, Puligheddu S, Khouri C, Carnovale C, et al.
- 699 Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna
- 700 dictionary [Internet], medRxiv; 2023 [cited 2023 Jun 15], p. 2023.06.07.23291076. Available
- 701 from: https://www.medrxiv.org/content/10.1101/2023.06.07.23291076v1
- 702 40. Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and
- transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57–69.
- 41. Church KW, Hanks P. Word Association Norms, Mutual Information, and Lexicography.
- 705 Comput Linguist. 1990;16:22–9.

- 706 42. Recchia G, Jones MN. More data trumps smarter algorithms: Comparing pointwise
- mutual information with latent semantic analysis. Behav Res Methods. 2009;41:647–56.
- 708 43. Role F, Nadif M. Handling the Impact of Low Frequency Events on Co-occurrence based
- 709 Measures of Word Similarity A Case Study of Pointwise Mutual Information. 2011.
- 710 44. Fusaroli M, Pelletti G, Giunchi V, Pugliese C, Bartolucci M, Necibi EN, et al. Deliberate
- 711 Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food
- and Drug Administration Adverse Event Reporting System. Drug Saf [Internet]. 2023 [cited
- 713 2023 Feb 2]; Available from: https://doi.org/10.1007/s40264-022-01269-x
- 714 45. Pauline O, Robert M, Bernardeau C, Hlavaty A, Fusaroli M, Roustit M, et al. Assessment
- of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the
- 716 WHO Pharmacovigilance Database. BioDrugs [Internet]. 2023 [cited 2023 Jun 12]; Available
- 717 from: https://doi.org/10.1007/s40259-023-00603-8
- 46. Orre R, Bate A, Norén GN, Swahn E, Arnborg S, Edwards IR. A bayesian recurrent
- 719 neural network for unsupervised pattern recognition in large incomplete data sets. Int J
- 720 Neural Syst. 2005;15:207–22.
- 721 47. van Borkulo CD, Borsboom D, Epskamp S, Blanken TF, Boschloo L, Schoevers RA, et
- al. A new method for constructing networks from binary data. Sci Rep. 2014;4:5918.
- 48. Newman MEJ, Girvan M. Finding and evaluating community structure in networks. Phys
- 724 Rev E. 2004;69:026113.
- 725 49. Newman MEJ. Fast algorithm for detecting community structure in networks. Phys Rev
- 726 E. 2004;69:066133.
- 50. Jaccard P. The Distribution of the Flora in the Alpine Zone. 1. New Phytol. 1912;11:37–
- 728 50.
- 729 51. Rezaei M, Fränti P. Set Matching Measures for External Cluster Validity. IEEE Trans
- 730 Knowl Data Eng. 2016;28:2173–86.
- 731 52. Gates AJ, Wood IB, Hetrick WP, Ahn Y-Y. Element-centric clustering comparison
- unifies overlaps and hierarchy. Sci Rep. 2019;9:8574.
- 733 53. Meilă M. Comparing Clusterings by the Variation of Information. In: Schölkopf B,
- Warmuth MK, editors. Learn Theory Kernel Mach. Berlin, Heidelberg: Springer; 2003. p.
- 735 173–87.
- 736 54. Telesford QK, Joyce KE, Hayasaka S, Burdette JH, Laurienti PJ. The Ubiquity of Small-
- 737 World Networks. Brain Connect. 2011;1:367–75.
- 738 55. Fusaroli M, Polizzi S, Menestrina L, Giunchi V. Unveiling the Hidden Toll of Drug-
- 739 Induced Impulse Control Disorders. 2023 [cited 2023 Aug 20]; Available from:
- 740 https://osf.io/k9v6s/
- 741 56. El Otmani H, sabiry S, Bellakhdar S, El Moutawakil B, Abdoh Rafai M. Othello
- syndrome in Parkinson's disease: A diagnostic emergency of an underestimated condition.
- 743 Rev Neurol (Paris). 2021;177:690–3.

- 744 57. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse
- control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol.
- 746 2010;67:589–95.
- 58. Santangelo G, Barone P, Trojano L, Vitale C. Pathological gambling in Parkinson's
- 748 disease. A comprehensive review. Parkinsonism Relat Disord. 2013;19:645–53.
- 749 59. Jiménez-Urbieta H, Gago B, Quiroga-Varela A, Rodríguez-Chinchilla T, Merino-Galán
- 750 L, Oregi A, et al. Pramipexole-induced impulsivity in mildparkinsonian rats: a model of
- 751 impulse control disorders in Parkinson's disease. Neurobiol Aging. 2019;75:126–35.
- 752 60. Riddle JL, Rokosik SL, Napier TC. Pramipexole- and methamphetamine-induced reward-
- mediated behavior in a rodent model of Parkinson's disease and controls. Behav Brain Res.
- 754 2012;233:15–23.
- 755 61. Marín-Lahoz J, Sampedro F, Martinez-Horta S, Pagonabarraga J, Kulisevsky J.
- 756 Depression as a Risk Factor for Impulse Control Disorders in Parkinson Disease. Ann
- 757 Neurol. 2019;86:762–9.
- 758 62. Blum AW, Jacobson K, Grant JE. Legal settlements and the reporting of adverse drug
- 759 events: Insights from the aripiprazole products liability litigation. Psychiatry Res.
- 760 2022;309:114411.
- 761 63. Norén GN, Meldau E-L, Chandler RE. Consensus clustering for case series identification
- and adverse event profiles in pharmacovigilance. Artif Intell Med. 2021;122:102199.
- 763 64. Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, et al. Impulse
- 764 control disorders in parkinson disease: A multicenter case-control study. Ann Neurol.
- 765 2011;69:986–96.
- 766 65. Masa JF, Pépin J-L, Borel J-C, Mokhlesi B, Murphy PB, Sánchez-Quiroga MÁ. Obesity
- 767 hypoventilation syndrome. Eur Respir Rev. 2019;28:180097.
- 768 66. de Jonge P, Alonso J, Stein DJ, Kiejna A, Aguilar-Gaxiola S, Viana MC, et al.
- Associations between DSM-IV mental disorders and diabetes mellitus: a role for impulse
- control disorders and depression. Diabetologia. 2014;57:699–709.
- 771 67. Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in
- Parkinson's disease. Mov Disord Off J Mov Disord Soc. 2009;24:1561–70.
- 773 68. Okai D, Samuel M, Askey-Jones S, David AS, Brown RG. Impulse control disorders and
- dopamine dysregulation in Parkinson's disease: a broader conceptual framework. Eur J
- 775 Neurol. 2011;18:1379–83.
- 776 69. De la Casa-Fages B, Grandas F. Dopamine Dysregulation Syndrome and Deep Brain
- 777 Stimulation of the Subthalamic Nucleus in Parkinson's Disease. Neurol Res Int [Internet].
- 778 2011 [cited 2021 Jun 16];2011. Available from:
- 779 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216377/
- 780 70. Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse
- 781 control disorders in Parkinson's disease. Mov Disord Off J Mov Disord Soc. 2015;30:121–7.

- 782 71. Yu XX, Fernandez HH. Dopamine agonist withdrawal syndrome: A comprehensive
- 783 review. J Neurol Sci. 2017;374:53–5.
- 784 72. Kataoka H, Sugie K. Delusional Jealousy (Othello Syndrome) in 67 Patients with
- 785 Parkinson's Disease. Front Neurol. 2018;9.
- 786 73. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of Nursing Home Placement in
- Parkinson's Disease: A Population-Based, Prospective Study. J Am Geriatr Soc.
- 788 2000;48:938–42.
- 74. Lopez AM, Weintraub D, Claassen DO. Impulse Control Disorders and Related
- 790 Complications of Parkinson's Disease Therapy. Semin Neurol. 2017;37:186–92.
- 791 75. Goerlich-Dobre KS, Probst C, Winter L, Witt K, Deuschl G, Möller B, et al.
- Alexithymia-an independent risk factor for impulsive-compulsive disorders in Parkinson's
- 793 disease. Mov Disord Off J Mov Disord Soc. 2014;29:214–20.
- 794 76. Vriend C, Pattij T, van der Werf YD, Voorn P, Booij J, Rutten S, et al. Depression and
- 795 impulse control disorders in Parkinson's disease: Two sides of the same coin? Neurosci
- 796 Biobehav Rev. 2014;38:60–71.
- 797 77. Plummer NR, Tam AW, Mulvaney CA, Preston NJ, Laha SK. Dopamine agonists for
- 798 traumatic brain injury. Cochrane Database Syst Rev [Internet]. 2018 [cited 2023 Apr 14];
- 799 Available from:
- https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013062/full
- 78. Feltenstein MW, Do PH, See RE. Repeated aripiprazole administration attenuates cocaine
- seeking in a rat model of relapse. Psychopharmacology (Berl). 2009;207:401–11.
- 803 79. Feltenstein MW, Altar CA, See RE. Aripiprazole blocks reinstatement of cocaine seeking
- in an animal model of relapse. Biol Psychiatry. 2007;61:582–90.
- 805 80. R: The R Project for Statistical Computing [Internet]. [cited 2023 Feb 4]. Available from:
- 806 https://www.r-project.org/
- 81. Welcome to Python.org [Internet]. Python.org. 2023 [cited 2023 Feb 4]. Available from:
- 808 https://www.python.org/

- 809 82. Csardi G, Nepusz T. The igraph software package for complex network research.
- 810 83. Revelle W. Procedures for Psychological, Psychometric, and Personality Research
- [Internet]. R package version 2.2.9. Northwestern University, Evanston, Illinois; 2022.
- 812 Available from: https://CRAN.R-project.org/package=psych
- 813 84. Fusaroli M, Giunchi V. DiAna: Repository for FAERS cleaning and analysis. 2023 [cited
- 814 2023 Aug 20]; Available from: https://osf.io/zqu89/
- 815 85. Fusaroli M, Giunchi V. DiAna R package: Advanced Disproportionality Analysis in the
- FAERS for Drug Safety. [Internet]. 2023 [cited 2023 Oct 21]. Available from:
- 817 https://github.com/fusarolimichele/DiAna\_package

## **Supporting Information**

- Table S1. Expressions of pathological impulsivity. MedDRA query and behavioral subqueries used for retrieving drug-induced impulsivity.
- Table S2. Manifestation of impulsivity in the two populations investigated.
- Table S3. Features of pramipexole reports. We compared cases of pramipexole-related pathological impulsivity vs any other report recording pramipexole. Chi-square test was performed for categorical values, Mann-Whitney for continuous ones, and p-values were corrected for multiple comparison using the Holm-Bonferroni method.
- Table S4. Features of aripiprazole reports. We compared cases of aripiprazole-related pathological impulsivity vs any other report recording aripiprazole. Chi-square test was performed for categorical values, Mann-Whitney for continuous ones, and p-values were corrected for multiple comparison using the Holm-Bonferroni method.
- Table S5. Events disproportionally reported with aripiprazole-induced impulsivity. Ordered by N.
- Table S6. Events disproportionally reported with pramipexole-induced impulsivity. Ordered by N.
- Table S7. Nodes with highest degree-centrality.
- Table S8. Aripiprazole edges. The ten strongest links for the three networks of aripiprazole are shown. Note that the links are undirected, therefore the two nodes may be switched.
- Table S9. Pramipexole edges. The ten strongest links for the three networks of pramipexole are shown.
- Note that the links are undirected, therefore the two nodes may be switched.
- Table S10. Aripiprazole clusters obtained from Ising and Phi estimation. Phi and Ising clusters are shown side by side. Ising clusters are color-coded, to show the similiarities with Phi.
- Table S11. Pramipexole clusters obtained from Ising and Phi estimation. Phi and Ising clusters are shown side by side. Ising clusters are color-coded, to show the similarities with Phi.
- Figure S1. The secondary impact of aripiprazole-induced pathologic impulsivity. The network shows the events disproportionally reported with aripiprazole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the three methods: Ising (A), Phi (B) and PPMI (C). The layout is calculated using a spring model with, as weight, the average of the three weights calculated, after rescaling them from 0 to 1.
- Figure S2. The secondary impact of aripiprazole-induced pathologic impulsivity, Ising estimation. The network shows the events disproportionally reported with aripiprazole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the Ising estimation. The layout is calculated using a spring model with, as weight, the links from the Ising.
- **Figure S3.** The secondary impact of aripiprazole-induced pathologic impulsivity, Phi estimation. The network shows the events disproportionally reported with aripiprazole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the Phi estimation. The layout is calculated using a spring model with, as weight, the links from the Phi.
- Figure S4. The secondary impact of aripiprazole-induced pathologic impulsivity, PPMI estimation. The network shows the events disproportionally reported with aripiprazole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the PPMI estimation. The layout is calculated using a spring model with, as weight, the links from the PPMI.
- Figure S5. The secondary impact of pramipexole-induced pathologic impulsivity. The network shows the
  events disproportionally reported with pramipexole-related impulsivity. Impulsivity is shown as squares, other
  events as circles. Node colors and contours identify the clusters for the three methods: Ising (A), Phi (B) and PPMI
  (C). The layout is calculated using a spring model with, as weight, the average of the three weights calculated,
  after rescaling them from 0 to 1.
- Figure S6. The secondary impact of pramipexole-induced pathologic impulsivity, Ising estimation. The network shows the events disproportionally reported with pramipexole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the Ising estimation. The layout is calculated using a spring model with, as weight, the links from the Ising.
- Figure S7. The secondary impact of pramipexole-induced pathologic impulsivity, Phi estimation. The network shows the events disproportionally reported with pramipexole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the Phi estimation. The layout is calculated using a spring model with, as weight, the links from the Phi.
- Figure S8. The secondary impact of pramipexole-induced pathologic impulsivity, PPMI estimation. The network shows the events disproportionally reported with pramipexole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the PPMI estimation. The layout is calculated using a spring model with, as weight, the links from the PPMI.
- Figure S9. Degree centrality, pramipexole.
- Figure S10. Degree centrality, aripiprazole.
- Figure S11. Sankey showing comparison between clusters in PPMI and PHI, pramipexole.
- Figure S12. Sankey showing comparison between clusters in PPMI and Ising, pramipexole.
- Figure S13. Sankey showing comparison between clusters in Phi and Ising, pramipexole.
- Figure S14. Sankey showing comparison between clusters in PPMI and PHI, aripiprazole.
- Figure S15. Sankey showing comparison between clusters in PPMI and Ising, aripiprazole.
- Figure S16. Sankey showing comparison between clusters in PHI and Ising, aripiprazole.